Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
52 studies found for:    " June 01, 2011":" July 01, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" June 01, 2011":" July 01, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
Conditions: HIV Enteropathy;   Diarrhea With HIV
Intervention: Drug: Crofelemer
2 Recruiting HIV, Buprenorphine, and the Criminal Justice System
Conditions: Human Immunodeficiency Virus;   Acquired Immunodeficiency Syndrome;   Opiate Addiction;   Drug Dependence
Intervention: Drug: Buprenorphine/naloxone
3 Active, not recruiting A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Conditions: Human Immunodeficiency Virus (HIV) Infections;   Acquired Immunodeficiency Syndrome (AIDS) Virus
Interventions: Drug: Darunavir;   Drug: Ritonavir
4 Completed
Has Results
A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients
Condition: Human Immunodeficiency Virus 1
Interventions: Drug: Darunavir(DRV);   Drug: Ritonavir;   Drug: 2 nucleoside reverse transcriptase inhibitors (NRTIs)
5 Completed Feasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected Women
Conditions: Human Immunodeficiency Virus (HIV);   Self-efficacy;   Self-esteem
Intervention: Behavioral: Ipod video
6 Active, not recruiting Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy
Condition: HIV Positive
Intervention: Drug: Vorinostat
7 Completed HIV Diagnosis in Hospitalized Malawian Infants
Condition: HIV Infections
Intervention: Device: Point of care HIV RNA PCR
8 Completed Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir
Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: Dolutegravir 50 mg tablet;   Drug: Dolutegravir 50 mg oral granules
9 Completed HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence
Conditions: Acute HIV Infection;   Acquired Immunodeficiency Syndrome;   Medication Adherence
Intervention: Behavioral: Advanced Adherence Counseling (AdvAdh)
10 Recruiting Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)
Condition: HIV Infection
Interventions: Drug: Maraviroc, Darunavir/r;   Drug: current antiretroviral therapy with 3 drugs
11 Completed Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice
Condition: HIV Infections
Intervention: Drug: darunavir/ritonavir plus background regimen
12 Recruiting HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Condition: Human Immunodeficiency Virus-1
Interventions: Drug: BMS-663068;   Drug: Raltegravir;   Drug: Tenofovir;   Drug: Ritonavir;   Drug: Atazanavir
13 Unknown  Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals
Conditions: Influenza, Human;   Human Immunodeficiency Virus I Infection
Intervention:
14 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
15 Completed Residual Risk Assessment Of HIV Transmission
Condition: HIV Infection
Intervention: Biological: blood and semen sampling, specific biological exams and biobank and self administered questionnaires
16 Recruiting REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
Condition: HIV Infection
Interventions: Drug: Atripla (r);   Drug: Efavirenz;   Drug: Truvada;   Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDC;   Drug: Rifampin/isoniazid FDC
17 Active, not recruiting Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials
Condition: HIV Infections
Interventions: Biological: Sub C gp140 Vaccine;   Biological: MF59C.1 Adjuvant
18 Completed Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers
Condition: HIV Infections
Interventions: Drug: Darunavir;   Drug: Ritonavir;   Drug: BI 201335
19 Unknown  Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
Condition: HIV Prevention
Interventions: Drug: Tenofovir gel;   Drug: Universal placebo gel
20 Completed Treating South African Pregnant Women for Methamphetamine
Conditions: HIV;   Drug Addiction
Interventions: Behavioral: Psycho-education;   Behavioral: Experimental

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years